Valion Bio Announces That The Armed Forces Radiobiology Research Institute Will Evaluate The Therapeutic Efficacy Of Entolimod
Benzinga Newsdesk 1 day ago
FDANews
This phase will evaluate whether treatment administered after radiation exposure improves survival in a model designed to assess gastrointestinal acute radiation syndrome ("GI-ARS").The therapeutic study is
This phase will evaluate whether treatment administered after radiation exposure improves survival in a model designed to assess gastrointestinal acute radiation syndrome ("GI-ARS").
The therapeutic study is fully funded by the National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program ("RNCP") under an Interagency Agreement with the Uniformed Services University ("USU")/AFRRI. Top-line results are anticipated in early December.
The decision to advance the program to the therapeutic phase comes just days after Valion announced positive safety results. Achieving this milestone uniquely positions Valion Bio, potentially further strengthening its competitive position, commercial opportunities, and fundamental outlook.
"NIAID's decision to move into therapeutic efficacy testing at AFRRI gives Entolimod a clear next milestone following the positive safety findings," said Dean Zikria, Interim Chief Executive Officer of Valion Bio. "The central question is now whether treatment after radiation exposure can improve survival in a model designed to isolate gastrointestinal injury. This fully funded study provides an opportunity to evaluate that potential while preserving Valion's capital and generating critical efficacy data to guide Entolimod towards its next stage of development."
Evaluating Entolimod's Potential to Improve Survival Following Radiation Exposure
Entolimod is being developed as a potential medical countermeasure for both the hematopoietic (or bone marrow) and gastrointestinal ("GI") forms of acute radiation syndrome ("ARS"). By shielding roughly 2.5% of the animals' bone marrow, the upcoming study's partial-body irradiation model will enable researchers to differentiate between effects linked to the mitigation of gastrointestinal injury and those associated with recovery.
Mice will receive a single administration of either Entolimod or saline control 24 hours after radiation exposure and then will be monitored for 30 days. The primary endpoint is survival, with outcomes to be compared between the treatment and control groups.